Home » Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

January 11, 2013

It’s a make or break year for GlaxoSmithKline. The UK’s largest pharmaceutical company is counting on a spate of drugs winning approval this year to reverse recent setbacks and revive growth.
Bloomberg

08Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers
11Oct
1st Annual Quality Management vSummit

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

1st Annual Quality Management vSummit

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

FDA Issues Update on Becton Dickinson’s Recall

FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements